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Abstract 28 
Purpose: PSA testing results in unnecessary biopsy and over-diagnosis with consequent over-29 
treatment. Tissue biopsy is an invasive procedure, associated with significant morbidity. More 30 
accurate non- or minimum-invasive diagnostic approaches should be developed to avoid 31 
unnecessary prostate biopsy and over-diagnosis. We investigated the potential of using 32 
circulating tumor cell analysis in cancer diagnosis, particularly in predicting clinically 33 
significant prostate cancer in pre-biopsy patients.  34 
Material and methods: We enrolled 155 treatment naïve prostate cancer patients and 98 35 
pre-biopsy patients for circulating tumor cell numeration. RNA was extracted from circulating 36 
tumor cells from 184 patients for gene expression analysis. Kruskal-Wallis, Spearman’s rank, 37 
multivariate logistic regression and random forest were applied to assess the association of 38 
circulating tumor cells with aggressive prostate cancer. 39 
Results: In localized prostate cancer patients, 54% were scored as circulating tumor cell 40 
positive, which was associated with higher Gleason score (p=0.0003), risk group (p<0.0001) 41 
and clinically significant prostate cancer (p<0.0001). In pre-biopsy group, positive circulating 42 
tumor cell score in combination with PSA predicted clinically significant prostate cancer with 43 
AUC=0.869. A 12-gene panel prognostic for clinically significant prostate cancer was also 44 
identified. Combining PSA level, circulating tumor cell-score and the 12-gene panel, AUC for 45 
clinically significant prostate cancer prediction was 0.927 and in cases with multi-parametric 46 
MRI data, adding these to multi-parametric MRI significantly increased the prediction 47 
accuracy (AUC 0.936 vs 0.629).  48 
Conclusions: Circulating tumor cell analysis has the potential to significantly improve patient 49 
stratification by PSA and/or multi-parametric MRI for biopsy and treatment. 50 
 51 
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1. Introduction 55 
PSA testing lacks specificity in the detection of prostate cancer (PCa), the most common 56 
cancer in Western men1, 2 and over half patients with elevated PSA levels do not have cancer 57 
on biopsy, an invasive procedure with significant risks of urinary retention, bleeding and 58 
infection. In addition more than50% of the patients diagnosed with early stage PCa will not 59 
die of the disease3-6 suggesting PSA may lead to unnecessary biopsies, over-diagnosis, and 60 
overtreatment7. Histological grading by Gleason score (GS) from biopsy specimens is currently 61 
needed for risk stratification, allowing the offer of appropriate therapeutic options7, 8. An 62 
accurate, non-invasive test for clinically significant PCa (csPCs) might provide a safer, more 63 
efficient means of diagnosis.  64 
 65 
Multiparametric MRI (mpMRI) has recently shown value in the detection of csPCA, with 66 
specificities of 23-87% and sensitivities of 58-96% reported9-11. The PROMIS trial of 576 men 67 
demonstrated a 93% sensitivity and 41% specificity of mpMRI, compared to 48% and 96% 68 
respectively for untargeted transrectal biopsy9 suggesting 27% could avoid biopsy using 69 
mpMRI as triage but with an accurate pre-biopsy biomarker a further 50% might do so.  70 
 71 
Circulating tumor cell (CTC) analysis using CellSearch system has been approved by FDA for 72 
prognostics in advanced, metastatic PCa12. The study of CTCs in non-metastatic PCa has been 73 
predominantly in locally advanced disease13-18. Most studies used CellSearch, concluding that 74 
CTCs are rare in patients with non-metastatic PCa13-15. Recent studies using new CTC isolation 75 
systems demonstrate greater CTC capture efficiency than CellSearch in locally advanced 76 
PCa16-18. Most methods detect CTCs with epithelial cell features, missing CTCs undergoing 77 
epithelial-mesenchymal transition (EMT), an important process in metastasis development. 78 
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We demonstrated that the Parsortix system, which uses cell size and deformability to capture 79 
CTCs, harvested different subtypes in greater numbers than CellSearch19, 20. Here we 80 
investigate its efficiency in capturing CTCs from patients with localized PCa and in PCa 81 
diagnosis and risk stratification.  82 
 83 
2. Materials and methods 84 
2.1 Study patient cohorts  85 
155 treatment-naïve, histologically confirmed localized PCa patients and 98 biopsy-naïve 86 
patients with concerning PSA levels and/or abnormal digital rectal examination were enrolled 87 
at St Bartholomew’s Hospital. MpMRI was performed before biopsy. Ultrasound guided 88 
transrectal or transperineal biopsy was performed with targeted biopsy on suspicious (Likert 89 
3+) mpMRI lesions. Two pre-biopsy patients had bone metastases demonstrated by bone 90 
scintigraphy. Control samples were collected from 12 healthy volunteers.  91 
 92 
Clinical data including age, PSA, radiological results, biopsy results and TNM stage were 93 
collected (Supplementary Table 1). Patients were classified into low-, intermediate-, and 94 
high-risk tumor following EAU guidelines7 and favorable disease or csPCa were defined based 95 
on previous publications21, 22 shown in Supplementary Table 2. The primary outcome was 96 
men diagnosed with PCa, including risk stratification into favorable/clinically significant 97 
disease.  98 
 99 
2.2 Cell lines  100 
Three PCa cell lines, PC3, LNCaP and VCaP from ATCC were used with authentication by short 101 
tandem repeat testing. 102 
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 103 
2.3 CTC isolation, enumeration and RNA extraction 104 
7.5 mL of whole blood was used for CTC isolation and enumeration as described 105 
previously19,20. Positive CTC-score was defined as any epithelial CTC (CK+/VIM-/CD45-), any 106 
EMTing CTC (CK+/VIM+/CD45-), and/or >3 mesenchymal CTCs (CK-/VIM+/CD45-) based on 107 
our previous analysis of 24 age-matched male healthy control samples and the confirmation 108 
of the malignant nature of CTCs in PCa cases by fluorescence in situ hybridization analysis of 109 
multiple genomic regions commonly altered in PCa cells20. 97/155 PCa patients and 87/98 110 
pre-biopsy patients had an extra 7.5 mL blood for CTC mRNA analysis harvested from cassette. 111 
Total RNA was extracted using miRNeasy micro kit (Qiagen) following manufacturer’s 112 
instructions but eluted with a final volume of 11.5 L. cDNA synthesis was performed using 113 
SuperScript™ II Reverse Transcriptase (ThermoFisher Scientific).  114 
 115 
2.4 Quantitative RT-PCR (qRT-PCR) for analytical validation  116 
Gene expression was determined either using ABI 7500 Real-Time PCR system (Life 117 
technologies) or Fluidigm multiplex PCR. 118 
 119 
2.5 Statistical analyses 120 
Kruskal-Wallis test was applied to assess the equality of CTCs between subgroups based on 121 
CTC-score and different clinical features, such as mpMRI data, primary GS, and risk 122 
classification. Data was shown as median (interquartile range [IQR]). Spearman’s rank 123 
correlation was used to assess the association between CTC counts and concurrent PSA level. 124 
Receiver operating characteristic (ROC) curve analysis was performed to test the ability of 125 
MRI, PSA, CTCs and different combined risk scores (CRSs) to predict patients with PCa and 126 
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csPCa. Regression coefficients for individual variables in CRSs were computed by multivariate 127 
logistic regression. Optimal cut-off point was calculated to provide best available sensitivity 128 
and specificity. Random forest classification algorithm23 was applied to rank prediction 129 
abilities of CTC expression genes  and the final gene set selection was conducted by 130 
comparing out-of-bag error rates of random forest models composed of decreasing number 131 
of genes. Bonferroni correction method was applied to adjust p values (padj) for multiple 132 
testing. Statistical analyses were performed using Stata 13.0 and R3.3.1. 133 
 134 
3. Results 135 
3.1 Detection of CTCs in patients with localized PCa and their correlations with risk groups  136 
We first investigated the ability of CTCs, analyzed in three categories: epithelial (CK+/VIM-137 
/CD45-), EMTing (CK+/VIM+/CD45-) and mesenchymal (CK-/VIM+/CD45-) CTCs (Fig. 1A) for a 138 
CTC score, in distinguishing clinically insignificant and significant cancers in diagnosed 139 
localized PCa patients. In 155 patients with localized PCa, at least one traditional epithelial 140 
CTC (all CK+ CTCs) were detected in 30% (46/155) of patients, at least one of any subtypes of 141 
our defined CTCs in 78% (121/155) of patients and 54% (84/155) of patients were CTC-score 142 
positive. In the 64 GS 3+3 and 40 low-risk cancer patients, CTCs were scored positive in 34% 143 
(22/64) and 25% (10/40) of cases respectively, indicating that cancer cells are released into 144 
the circulation at an early development stage. 145 
 146 
Considering subtypes of CTCs, epithelial, EMTing and mesenchymal CTCs all showed trends of 147 
correlations (Spearman’s ϱ=0.15, 0.24 and 0.11, respectively) with serum PSA levels (p=0.07, 148 
0.0029 and 0.17 respectively), although only EMTing CTCs are significant. Epithelial, EMTing 149 
and mesenchymal CTC counts generally increased from low to high GS groups (3+3, 3+4, 4+3, 150 
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and ≥4+4) but without statistical significance (padj=0.16, 0.06 and 0.24 respectively, 151 
Supplementary Fig. 1).  Positive CTC-score was significantly associated with high GS 152 
(padj=0.0012, Table 1).  153 
 154 
If the 155 patients were divided into low-, intermediate- and high-risk groups, EMTing and 155 
mesenchymal CTCs significantly increased with higher risk (padj=0.0136 and 0.016 respectively) 156 
but not epithelial CTCs (padj=0.44, Table 1, Fig. 1B). CTC-score positivity associated more 157 
significantly (padj<0.0001) with high-risk disease. Dividing into clinically significant and 158 
favorable disease, high PSA level (p=0.0001), positive CTC-score (padj<0.0001), epithelial 159 
(padj=0.0264), EMTing (padj=0.01) and mesenchymal (padj=0.0384) CTC counts were all 160 
significantly correlated to csPCa (Table 1, Fig. 1C). Combining CTC-score with PSA, we 161 
generated the combined risk score (CRS-PC) by 0.233xPSA + 1.548xCTC-score, which 162 
discriminated csPCa better than PSA alone (AUC: 0.826 vs 0.764, p=0.03, Fig. 2A). In the 115 163 
patients with mpMRI data at diagnosis, a significantly higher MRI positive (using Likert=3 as 164 
threshold) rate was found in csPCa (P=0.0001) than favorable patients (Table 1). The AUC 165 
using Likert 1-5 was 0.753 (95%CI: 0.663-0.842, with a cut-off point ≥3 to reach sensitivity of 166 
98.59% and specificity of 47.73%, or a cut-off point ≥5 to reach sensitivity of 7.04% and 167 
specificity of 100%). 168 
   169 
3.2 Predicting csPCa in pre-biopsy patients using serum PSA and CTC positivity 170 
We then assessed the potential of using CTCs to predict csPCa in 98 pre-biopsy patients. 171 
Positive CTC-score was significantly associated with a positive biopsy results (padj<0.0001) and 172 
csPCa (padj<0.0001, Table 2). Positive MRI (Likert≥3) had similar distribution in benign and 173 
malignant patients (p=0.52), but was significantly more frequent in csPCa than in favorable 174 
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disease (p=0.0002, Table 2) and favourable combined with benign patients (p=0.0017, Table 175 
2). The AUC to identify csPCa by PSA level was 0.733 (95%CI: 0.630-0.835, with an optimal 176 
cut-off point ≥15 ng/mL to reach 44.19% sensitivity and 96.36% specificity), by CTC-score was 177 
0.811 (95%CI: 0.732-0.890 with 76.74% sensitivity and 85.45% specificity) and by CRS-PC was 178 
0.869 (95%CI: 0.792-0.945, with an optimal cut-off point ≥2.87 to reach 87.27% sensitivity 179 
and 83.67% specificity)(Fig. 2B), using the model developed previously in localized patients, 180 
significantly (p=0.0008) better than PSA alone. In the 87 pre-biopsy patients with pre-biopsy 181 
MRI data, the AUC to predict csPCa using Likert 1-5 was 0.698 (95%CI: 0.588-0.808, with a 182 
cut-off point ≥3 to reach sensitivity of 97.2% and specificity of 29.4%, or a cut-off point ≥5 to 183 
reach sensitivity of 47.2% and specificity of 90.2%), PSA 0.739 and CTC-score 0.783 (Fig. 2C). 184 
Various combinations of these three factors were produced; CRS-PM (combining PSA and MRI 185 
Likert as 0.201xPSA + 0.550xMRI Likert), CRS-PC (combining PSA and CTC-score as 0.179xPSA 186 
+ 2.798xCTC-score), CRS-MC (combining MRI Likert and CTC-score as 0.593xMRI Likert + 187 
2.528xCTC-score) and CRS-PMC (combining PSA, MRI Likert and CTC-score as 0.207xPSA + 188 
2.477xCTC-score + 0.551xMRI Likert), in predicting csPCa. Each combination increased the 189 
prediction value (p<0.01 for all combinations including CTC score compared to PBS or MRI).  190 
AUC for the combination of all three factors (CRS-PMC) reached 0.891 (Fig. 2C).  191 
 192 
3.3 Using CTC gene expressions to improve the prediction of csPCa  193 
We identified 74 PCa prognostic genes through extensive bioinformatic analysis of all 194 
available transcriptome sequencing data and 50 reported PCa-specific and/or prognostic 195 
genes by literature search (Supplementary Table 3). 38 of the 124 genes were selected based 196 
on their relatively high expression in prostate and low/zero expression in WBC/whole blood 197 
using Genecards data (http://www.genecards.org/, Supplementary Table 3) for experimental 198 
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validation by qRT-PCR in PC3, LNCaP, VCaP and PBMC samples (Supplementary Fig. 2). Out of 199 
the 38 genes, 30 with low expression in PBMC (minimum median Ct of 33.9, Table 3, 200 
Supplementary Fig. 2) were finally selected for further analysis together with housekeeping 201 
genes GAPDH and MRFAP1. Good qRT-PCR amplification efficiency was achieved both for the 202 
ABI 7500 and Fluidigm systems using FOLH1 (PSMA) assay in 1, 5 10, and 20 spiked LNCaP 203 
samples (Supplementary Fig. 3). Minimum detectability of spiked cells for each gene using 204 
the Fluidigm system were shown in Supplementary Table 4. All the 30 genes were negative 205 
in PBMC controls. CDH12, CHGA, CSMD3, GRHL2, KLK2, and PART1 were only positive in 206 
cancer patients and csPCa cases were more frequently (17/108, 15.7%) with >6 gene positive 207 
than the remaining patients (6/76, 8%)(p=0.049).  208 
 209 
Using random forest classifier, we identified a 12-gene panel (Table 3, Supplementary Fig. 4) 210 
to distinguish csPCa from favorable disease with an AUC of 0.707 (95%CI: 0.634-0.779, with 211 
an optimal cut-off point ≥0.442, sensitivity 51.85%, specificity 80.26%). When we combined 212 
PSA level, CTC-score and 12-gene panel score as CRS-PCG (0.200xPSA + 2.082xCTC-score + 213 
1.035x12-gene panel score) the AUC increased from CRS-PC AUC=0.844 to 0.881 (95%CI: 214 
0.832-0.929 with an optimal cut-off point ≥3.154 to reach 83.33% sensitivity and 80.26% 215 
specificity, Fig. 2D)(p=0.024) in above 184 samples and it increased to 0.927 (95%CI: 0.870-216 
0.985, with an optimal cut-off point ≥3.095 to reach 87.5% sensitivity and 89.36% specificity) 217 
from a CRS-PC of 0.899 in the 87 pre-biopsy patients with CTC gene expression data (Fig. 218 
2E)(p=0.23). In the 78 samples with both MRI results and RNA samples, adding PSA and CTC 219 
data to mpMRI (valued as 1 if Likert≥3 and 0 otherwise) as CRS-PCGM=3.127xMRI likert + 220 
0.276xPSA + 3.014xCTC-score + 1.174x12-gene panel) dramatically increased AUC from 0.629 221 
to 0.936 (p<0.0001)(Fig. 2F). 222 
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 223 
3.4 Clinical implications  224 
Modelling CTC score use in the 98 pre-biopsy men, 85% of biopsies were avoided, but 23% 225 
of csPCas were missed, reflecting a high specificity but low sensitivity (Table 4).  Combining 226 
PSA and CTC score increased biopsies avoided to 87% while missing 23% of csPCa (Table 4). 227 
With the additional 12-gene panel, 91% biopsies were avoided with 18% csPCa missed. 228 
mpMRI predicted csPCa at a high sensitivity ( 94% negative predictive value) but lower 229 
specificity compared to CTC-score, avoiding 27% vs 85% biopsies (Table 4). Adding PSA and 230 
CTC data to mpMRI (CRS-PMC), 89% biopsies were avoided with only 15% csPCa missed (Table 231 
4). With an alternative cut-off point, CRS-PCGM could avoid 42% biopsies without missing 232 
csPCa, doubling that by MRI alone.   233 
 234 
4. Discussion 235 
The recent development of efficient CTC capture systems permits study of CTCs in non-236 
metastatic PCa, but its value in PCa detection is yet to be evaluated16-18. Using a cell size and 237 
deformability-based CTC isolation system in a large cohort of localized PCa, we detected CTCs 238 
at a high frequency and in low GS and low-risk cancer patients. Most importantly, we showed 239 
that CTC analysis in combination with serum PSA can efficiently detect csPCa, potentially 240 
avoiding prostate biopsy, and bringing major benefits to the PCa diagnostics. Cancer can 241 
invade the blood circulation at early development stages, including cancer precursor 242 
conditions24. However, due to their rarity and challenges in capturing CTCs, their potential for 243 
cancer detection has only been explored in lung malignancy12, 25, 26. Our study further supports 244 
the application of CTCs to early cancer detection.  245 
 246 
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High (>50%) negative biopsy rates in abnormal PSA (>4ng/ml) highlight its limitation as a 247 
biopsy trigger9. Additionally, many early-stage PCas are indolent, do not affect mortality3. A 248 
non-invasive biomarker, which can be used to avoid unnecessary biopsies, over-diagnosis, 249 
and over-treatment, would be a useful addition to the diagnostic pathway, allowing resources 250 
to be focused on patients with csPCa9. mpMRI shows promise in triaging patients with 251 
suspected PCa for prostate biopsy and play an increasing role9-11. Here, we show that CTCs 252 
may efficiently predict biopsy results, particularly for csPCa, and improve csPCa prediction 253 
value of mpMRI. Further study in large cohorts is warranted to establish the roles of CTCs in 254 
csPCa prediction alongside mpMRI, to improve patient biopsy triage and cancer prognosis.  255 
 256 
The prognostic value of cancer RNA expression has been demonstrated27, 28 and AR-V7 257 
expression in CTCs has been used to predict the response to androgen deprivation therapy. 258 
Here we demonstrate that, in addition to CTC enumeration, CTC gene expression analysis may 259 
provide further prognostic information and bypass the problem of tumor heterogeneity 260 
which occurs when analysing prostate biopsy samples29. Future CTC analysis in combination 261 
of both CTC enumeration and gene expression level may significantly increase the potential 262 
of using CTCs for cancer diagnosis and prognosis. 263 
 264 
Including mesenchymal CTCs, our study significantly increased the CTC positive cases in both 265 
the localized PCa and pre-biopsy cohorts of cancer cases.  Mesenchymal cancer cells show 266 
invasive growth properties and may cause spread at early stage of cancer development30.  In 267 
our localized disease cohort, only EMTing and mesenchymal CTCs were significantly 268 
associated with GS. 269 
 270 
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There are limitations to this study. Firstly, our CTC analysis may miss small CTCs. Secondly, 271 
The CTC gene expression panel is yet to be validated. Finally, this is a single centre study, 272 
which requires validation by independent research centres.  273 
 274 
5. Conclusion 275 
In a large series of localized PCa, we detected using our novel CTC analysis method, a high 276 
CTC positive rate which was correlated with higher GS and aggressive cancer. Importantly, 277 
positive CTC-score was associated with csPCa. In the pre-biopsy cohort, CTCs in combination 278 
with PSA efficiently predict csPCa. A CTC 12-gene prognostic panel was also identified to 279 
further increase the prediction accuracy of csPCa, which can be used to improve mpMRI 280 
prediction value. Therefore, we demonstrate the value of CTCs in PCa detection and 281 
prognostication. 282 
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Table 1. Summary of CTC count in 155 treatment-naïve prostate cancer patients by risk groups 
 Spearma
n’s ϱ 
with PSA 
(p) 
GS = 3+3  
(n = 64) 
GS = 3+4 
(n = 51) 
GS = 4+3 
(n = 22) 
GS ≥ 4+4  
(n = 18) 
p 
(padja) 
Low-risk  
(n = 40) 
Interme
diate-
risk 
(n = 78) 
High-risk 
(n = 37) 
p 
(padja) 
FD 
(n = 63) 
csPCa 
(n = 92) 
p  
(padja) 
Age, y      0.0078    0.0021   0.0076 
 Median (IQR)  61 (56-
68) 
66 (56-
71) 
63.5 (57-
71) 
69 (62-
76.5) 
 60 (55-
67) 
65 (56-
71) 
68 (61.5-
73) 
 61 (55-
68) 
66 (58-72)  
PSA, ng/mL      0.0001    0.0001   0.0001 
 Median (IQR)  6.7 (5-
9.9) 
8.3 (5.6-
12) 
12 (7.7-
18.3) 
18.8  
(8.9-26) 
 5.5 (4.7-
7.4) 
9.1 
(6.2-12) 
17.6 
(8.1-26) 
 6.5 (5-
9.0) 
10.5 (7.0-
17.5) 
 
mpMRI, n (%)      0.0001    0.0001   0.0001 
    1,2  22 (34) 0 (0) 0 (0) 0 (0)  16 (40) 6 (8) 0 (0)  21 (33) 1 (1)  
    3,4,5  21 (33) 43 (84) 17 (77) 12 (67)  10 (25) 60 (77) 23 (62)  23 (37) 70 (76)  
    n/a  21 (33) 8 (16) 5 (23) 6 (33)  14 (35) 12 (15) 14 (38)  19 (30) 21 (23)  
Epithelial CTC 0.15     
(0.07) 
    0.0425 
(0.17) 
   0.11      
(0.44) 
  0.0066 
(0.0264) 
 Median (IQR) 
(% detected) 
 0 (0-0) 
(14%) 
0 (0-1) 
(29.4%) 
0 (0-0.5) 
(23%) 
0 (0-2) 
(44%) 
 0 (0-0) 
(15%) 
0 (0-0) 
(23%) 
0 (0 -1) 
(35%) 
 0 (0-0) 
(13%) 
0 (0-1) 
(32%) 
 
EMTing CTC 0.24 
(0.0029) 
    0.0155 
(0.06) 
   0.0034 
(0.0136) 
  0.0025 
(0.01) 
 Median (IQR) 
(%) 
 0 (0-0) 
(6%) 
0 (0-0) 
(12%) 
0 (0-0) 
(18%) 
0 (0-1.3) 
(67%) 
 0 (0-0) 
(2.5%) 
0 (0-0) 
(12%) 
0 (0-1) 
(27%) 
 0 (0-0) 
(3%) 
0 (0-0) 
(20%) 
 
mesenchymal 
CTC 
0.11       
(0.17) 
    0.0608 
(0.25) 
   0.0040 
(0.016) 
  0.0096 
(0.0384) 
 Median (IQR) 
(%) 
 1 (0-2) 
(61%) 
1 (0-4) 
(66%) 
3 (0-10.5) 
(68%) 
3 (0.75-7) 
(94%) 
 1 (0-2) 
(55%) 
2 (0-4.3) 
(64%) 
4 (0-7.5) 
(73%) 
 1 (0-2) 
(57%) 
2 (0-5) 
(68%) 
 
CTC-score, n (%)      0.0003b 
(0.0012) 
   <0.0001b 
(<0.0001) 
  <0.0001b 
(<0.0001) 
    Negative   42 (66) 19 (37) 5 (23) 5 (28)  30 (75) 33 (42) 8 (22)  44 (70) 27 (29)  
    Positive  22 (34) 32 (63) 17 (77) 13 (72)  10 (25) 45 (58) 29 (78)  19 (30) 65 (71)  
 
a p value adjusted for multiple testing using Bonferroni correction method; b Fisher’s exact test. 
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PSA: prostate specific antigen; GS: Gleason score; n: number; FD: favorable disease; csPCa: clinically significant prostate cancer; IQR: interquartile range; mpMRI: Multi-
Parametric magnetic resonance imaging; n/a: data not available; CTC: circulating tumor cell; EMTing: during epithelial-mesenchymal transition.
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Table 2. Summary of CTC count in 98 pre-biopsy patients by biopsy results 
                                   
                                   a p value adjusted for multiple test; b Fisher’s exact test. 
                                    N: number; FD: favorable disease; csPCa: clinically significant prostate cancer; IQR: interquartile range; PSA: prostate specific antigen; mpMRI: Multi-Parametric 
                        magnetic resonance imaging; n/a: data not available; CTC: circulating tumor cell; EMTing: during epithelial-mesenchymal transition.  
     
 Benign biopsy  
(n = 33) 
Malignant 
biopsy 
(n = 65) 
p  
(padja) 
FD  
(n = 22) 
csPCa 
(n = 43) 
p  
(padja) 
FD+Benign 
biopsy 
(n=55) 
csPCa 
(n=43) 
p 
(padja) 
Age, y   0.06   0.021   0.0097 
   Median (IQR) 65 (56-69) 65 (59.5-70)  63 (56-66) 68 (63-71)  63 (57-68) 68 (63-71)  
PSA, ng/mL   0.0173   0.0017   0.0001 
   Median (IQR) 6.5 (5.2-10.2) 9.3 (6.4-17)  7.2 (6.0-9.4) 11 (7.0-23)  7.2 (5.4-10) 11 (7.0-23)  
Abnormal PSA, n (%)   1.0b   0.0108b   0.0333 
   > 4 ng/mL 31 (94) 61(94)  18 (82) 43 (100)  49 (89) 43 (100)  
   ≤ 4 ng/mL 2 (6) 4 (6)  4 (18) 0 (0)  6 (11) 0 (0)  
mpMRI, n (%)   0.52   0.0002   0.0017 
  1,2 7 (21)     9 (14)  8 (36) 1 (2)  15 (27) 1 (2)  
  3,4,5 25 (76) 46 (71)  11 (50) 35 (82)  36 (66) 35 (82)  
  n/a 1 (3) 10 (15)  3 (14) 7 (16)  4 (7) 7 (16)  
Epithelial CTC   0.0146    
(0.06) 
  0.0147   
(0.06) 
  0.0002 
(0.0008) 
   Median (IQR)(%) 0 (0-0)(3%) 0 (0-0)(22%)  0 (0-0)(5%) 0 (0-1)(30%)  0 (0-0)(4%) 0 (0-1)(30%)  
EMTing CTC   0.0181    
(0.07) 
  0.0806      
(0.32) 
  0.0019 
(0.0076) 
   Median (IQR)(%) 0 (0-0)(0%) 0 (0-0)(15%)  0 (0-0)(5%) 0 (0-0)(21%)  0 (0-0)(2%) 0 (0-0)(21%)  
Mesenchymal CTC   0.0022 
(0.0088) 
  0.0105 
(0.042) 
  0.0001 
(0.0004) 
   Median (IQR)(%) 0 (0-1.5)(36%) 2 (0-6)(63%)  0 (0-2.25)(45%) 3 (0-7)(72%)  0 (0-2)(40%) 3 (0-7)(72%)  
CTC-score, n (%)   <0.0001b  
(<0.0001) 
  <0.0001b  
(0.0002) 
  <0.0001b  
(<0.0001) 
   Negative 30 (91) 27 (41.5)  17 (77) 10 (23)  47 (85) 10 (23)  
   Positive 3 (9) 38 (58.5)  5 (23) 33 (77)  8 (15) 33 (77)  
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Table 3. Threshold cycle of candidate genes in PBMC and regression coefficients of genes in 12-gene panel 
 
Genes in 12-
gene panel 
CT in PBMC, 
median (range) 
Regression 
coefficient in panel 
Rest genes in 
test 
Ct in PBMC, 
median (range) 
Genes not 
included in test 
Ct in PBMC, 
median (range) 
AOX1 35.2 (34.9-36.1) 0.854 AR-V7 undetermined CPLX1 33.7 (33.0-35.1) 
ACOX2 34.8 (33.4-36.9) -1.89 CDH12 Undetermined COL5A2 33.0 (32.7-34.1) 
EYA4 36.3 (34.5-undetermined) 1.25 CHGA Undetermined ACTG2 33.0 (32.4-33.9) 
FAT1 34.8 (34.1-36.5) 0.265 CSMD3 undetermined WNT5A 33.3 (32.6-36.0) 
FOXA1 34.9 (32.8-36.2) -0.389 CYP3A5 Undetermined FRMD6 32.4 (32.3-33.1) 
GRHL2 Undetermined 0.934 LCE2B undetermined SYP 32.3 (31.8-32.7) 
HOXB13 36.1 (35.8-36.5) -0.146 MSMB Undetermined AR 31.8 (29.9-32.6) 
KLK2 35.8(35.4-37.2) 0.71 PART1 Undetermined CDH1 31.5 (30.2-33.1) 
MNX1 35.6 (34.6-37.1) -7.8 ROBO2 undetermined   
FOLH1(PSMA) 36.6 (35.4-37.2) 0.078 TMPRSS2:ERG undetermined   
RAB3B 34.5 (34.0-36.5) 0.693 KLK3 (PSA) 37.3 (37.2-37.9)   
SRD5A2 Undetermined -16.708 TWIST2 36.3 (35.3-37.8)   
   SPOCK3 35.9 (35.0-36.4)   
   FAM107A 35.3(35.0-undetermined)   
   HSPB8 37.0 (35.6-undetermined)   
   PCDH18 34.7 (32.2-37.1)   
   PCA3 34.5 (32.7-35.0)   
   TBX3 33.9 (30.8-37.1)   
                                    
         PBMC: peripheral blood mononuclear cell. 
          Genes in bold were those not selected due to relative lower Ct value.  
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Table 4. Clinical implications of CTC enumeration and gene expression in 98 pre-biopsy patients 
 Benign biopsies 
avoided (n = 33) (%) 
prostate cancers 
missed (n = 65) (%) 
PPV NPV FD+benign biopsy diagnosis 
avoided (n = 55) (%) 
csPCa missed 
(n = 43) (%) 
PPV NPV 
PSA > 4 ng/mL  2 (6) 4 (6) 66% 33% 6 (11) 0 (0) 47% 100% 
CTC-score (positive) 30 (91) 27 (42) 93% 53% 47 (85) 10 (23) 80% 82% 
CRS-PC ≥ 2.87 29 (88) 29 (45) 90% 50% 48 (87) 10 (23) 83% 83% 
 n = 28 n = 59   n = 47 n = 40   
CRS-PCG ≥ 3.154 25 (89) 25 (38) 92% 50% 43 (91) 7 (18) 89% 86% 
CRS-PCG ≥ 1.072 - - - - 11 (23) 0 (0) 53% 100% 
 n = 32 n = 55   n = 47 n = 40   
MRI positive (likert ≥ 3) 7 (22) 9 (16) 65% 44% 15 (27) 1 (3) 49% 94% 
 n = 28 n = 50   n = 45 n = 33   
CRS-PCGM ≥ 7.327 25 (89) 20 (40) 91% 56% 40 (89) 5 (15) 85% 89% 
CRS-PCGM ≥ 4.582 - - - - 19 (42) 0 (0) 56% 100% 
N: number; PPV: positive predictive value; NPV: negative predictive value; FD: favorable disease; csPCa: clinically significant prostate cancer; CRS: combined risk score; CRS-
PC: combining PSA and CTC-score; CRS-PCG: combining PSA, CTC-score, and 12-gene panel score; CRS-PCGM: combining MRI, PSA, CTC-score and 12-gene panel score. 
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Figure legend  
 
Figure 1. Representative CTC images and the distribution of subtypes of CTCs in PCa patient 
groups with different progression risk. (A) Representative CTC images identified by 
immunofluorescence. (B) The distribution of epithelial, EMTing and mesenchymal CTCs in 
patient groups with low, intermedium and high progression risk PCa. (C) The distribution of 
epithelial, EMTing and mesenchymal CTCs in patient groups with favorable cancer and csPCa. 
In B and C, data are expressed as mean (middle horizontal bar) ± SD (top and bottoms). X-axis: 
Gleason score groups; Y-axis: CTC numbers in each patient. 
 
Figure 2. AUCs of CTCs and in combinations with other parameters for csPCa prediction in 
treatment-naïve prostate cancer and pre-biopsy patients. AUCs in predicting csPCa in 155 
localized PCa patients (A), 98 pre-biopsy patients (B), 87 patients with MRI, PSA and CTC-score 
data(C), 184 patients with CTC gene expression data(D), 87 pre-biopsy patients(E) and the 78 
samples with MRI, PSA, CTC-score and gene expression data (F). CRS-PC: PSA combined with 
CTC; CRS-PM: PSA combined with MRI likert; CRS-MC: MRI likert combined with CTC-score; 
CRS-PMC: PSA combined with MRI likert and CTC-score; CRS-PCG: PSA combined with CTC 
count and 12-gene panel score; CRS-PCGM: MRI combined with PSA, CTC-score and 12-gene 
panel score. 
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Key of Definitions for Abbreviations 
AUC                   Area under the ROC curve 
CRS  combined risk score 
csPCa  clinically significant prostate cancer 
CTC  circulating tumor cell 
EMT  epithelial-mesenchymal transition 
GS  Gleason score 
IQR  interquartile range 
mpMRI Multi-Parametric MRI 
PBMC  peripheral blood mononuclear cells 
PCa  prostate cancer 
QRT-PCR quantitative RT-PCR 
ROC  receiver operating characteristic 
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